Member Login（https://members.medaus.com.au/）
Research & Development Taskforce (RDTF)
Research & Development Taskforce (RDTF)
Policy（https://www.medicinesaustralia.com.au/policy/） Strategic Agreement 2022-2027（https://www.medicinesaustralia.com.au/policy/strategic-agreement-2022-2027/）
Health Technology Assessment (HTA)（https://www.medicinesaustralia.com.au/policy/health-technology-assessment-hta/）
Access to Medicines Working Group (AMWG)（https://www.medicinesaustralia.com.au/policy/access-to-medicines-working-group-amwg/）
Clinical Trials（https://www.medicinesaustralia.com.au/policy/clinical-trials/） Clinical Trial Research Agreements（https://www.medicinesaustralia.com.au/policy/clinical-trials/clinical-trial-research-agreements/）
Indemnity & Compensation Guidelines（https://www.medicinesaustralia.com.au/policy/clinical-trials/indemnity-compensation-guidelines/）
Research & Development Taskforce (RDTF)（https://www.medicinesaustralia.com.au/policy/clinical-trials/research-development-task-force-rdtf/）
Teletrials（https://www.medicinesaustralia.com.au/policy/clinical-trials/tele-trials/）
Oncology Industry Taskforce（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/） Addressing the challenges of access to new cancer medications（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/addressing-the-challenges-of-access-to-new-cancer-medications/）
About the OIT（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/about-the-oit/）
Reports and resources（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/reports-and-resources/）
Pharma Australia Inclusion Group (PAIG)（https://www.medicinesaustralia.com.au/policy/pharma-australia-inclusion-group-paig/）
Policy Submissions（https://www.medicinesaustralia.com.au/policy/submissions/）
Regenerative Medicines Consortium Programme（https://www.medicinesaustralia.com.au/policy/regenerative-medicines-consortium-programme/）
The Research & Development Taskforce (RDTF) is a multi-sector collaboration between Medicines Australia, AusBiotech（https://www.ausbiotech.org/） and the Medical Technology Association of Australia（https://www.mtaa.org.au/） (MTAA). The membership consists of research and development experts, particularly in clinical trials, and offers a unique industry perspective to stakeholders across Federal and State Governments as well as the broader health and research and development sector.
Please contact Medicines Australia（https://www.medicinesaustralia.com.au/about-us/contact/）, for more information about the RDTF.
RDTF position on Supporting Clinical Trials During the COVID19 Pandemic
Clinical trials remain critical in the path to bringing innovative drugs, vaccines and therapies to consumers and patients in Australia in a safe and regulated manner. Given the anticipated growing impact of COVID-19 on the health system and a range of services, Clinical Trial Sponsors are working with their doctors and nurses to prepare for disruption to normal research activities due to this pandemic. At all times, the safety and continuity of care of clinical trial participants is the key concern of Clinical Trial Sponsors and clinical trial centre staff.
Clinical Trial Sponsors are committed to the delivery of clinical research and will work to ensure that the clinical trials already underway are managed as well as can be during the pandemic. Clinical Trial Sponsors are working closely with clinical trial centre staff to understand what additional support can be provided to overcome the challenges that are presenting due to COVID-19 disruptions.